clinical trial · NCT07459647
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
SchizophreniaML-007C-MA
brief summary
ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).
started
Mar 31, 2026
primary completion
Feb 1, 2030
completion
Feb 1, 2030
last updated
Apr 22, 2026
official title
An Open-Label Study to Assess the Long-Term Safety, Tolerability, and Effectiveness of ML-007C-MA in Adult Participants With Schizophrenia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol